AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00567528
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
Trial: NCT00567528
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
Trial: NCT00478101
Drug: oxycodone fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01125943
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial infusion
Trial: NCT00332839
Drug: Enteric Coated - Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose was ≥ 720 mg/day.
Trial: NCT00046371
Drug: THERATOPE® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455141
Drug: Epirubicin plus Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
Trial: NCT02455141
Drug: Taxanes
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
Trial: NCT00332839
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.
Trial: NCT00303381
Drug: Interferon-beta-1a, 44 microgram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
Trial: NCT00303381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
Trial: NCT00303381
Drug: Interferon-beta-1a, 66 microgram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Trial: NCT03447470
Drug: RXC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
Trial: NCT03363425
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04246255
Drug: Xylocaine 10% Oral
RxNorm normalized name: Xylocaine 10% Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Trial: NCT04246255
Drug: Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Trial: NCT01606215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00558571
Drug: placebo to BI 10773
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00817466
Drug: Racemic adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.
Trial: NCT00817466
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml NaCl 9mg/ml.
Trial: NCT02514954
Drug: Biochaperone® Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of an individualized dose
Trial: NCT02514954
Drug: Humalog® Mix25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of an individualized dose
Trial: NCT01154127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Trial: NCT04464707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02581839
Drug: Pre-Medication: Zofran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofran at 8mg orally. Given at the discretion of the treating physician
Trial: NCT02581839
Drug: Pre-Medication: Decadron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: decadron at 8mg orally. Given at the discretion of the treating physician
Trial: NCT03448081
Drug: SNA-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNA-120 (0.5%) active ointment
Trial: NCT03448081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ointment
Trial: NCT00796354
Drug: MOVICOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
Trial: NCT04592549
Drug: ADM03820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
Trial: NCT03804944
Drug: Pembrolizumab (200mg IV for 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
Trial: NCT02536833
Drug: SM04690
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02536833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00695201
Drug: Floxuridine, Oxaliplatin, CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
Trial: NCT00695201
Drug: Floxuridine, Oxaliplatin, CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
Trial: NCT00938964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine versus placebo infusion for 48 hours
Trial: NCT03455764
Drug: MCS110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
Trial: NCT00655135
Drug: LDP-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
Trial: NCT00655135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
Trial: NCT01211587
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
Trial: NCT00730262
Drug: TLN-4601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
Trial: NCT03524118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
Trial: NCT00453388
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01309828
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets.
Trial: NCT04452929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of saline placebo.
Trial: NCT00811070
Drug: SKI-606 (Bosutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing.
Trial: NCT01522586
Drug: DWP09031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Trial: NCT01522586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Trial: NCT01845701
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
Trial: NCT02582801
Drug: 18F-Alfatide Ⅱ PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Trial: NCT04582409
Drug: HSY244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSY244 concentrate solution for injection via intravenous infusion
Trial: NCT01771185
Drug: Best medical treatment (Metformin ; gliclazide)
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2 g/day; gliclazide 30 mg
Trial: NCT04219280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid solution to mimic the color and taste of Quillivant XR.
Trial: NCT00238511
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02407028
Drug: Normobaric Hyperoxia (NBH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
Trial: NCT01759485
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01511185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose administered subcutaneously in random order
Trial: NCT02577783
Drug: PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
Trial: NCT02577783
Drug: PAD regimen: bortizomib, dexamethasone and doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
Trial: NCT01163032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, PO daily for 6 months
Trial: NCT00621894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00198978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00198978
Drug: Dexamethasone / Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00392821
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001
Trial: NCT01753739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
Trial: NCT00371501
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/day
Trial: NCT00371501
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet/day
Trial: NCT00371501
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02021656
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily without regard to food
Trial: NCT01687374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection daily for 8 weeks.
Trial: NCT00198978
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00198978
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01881048
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03457233
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
Trial: NCT00124566
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
Trial: NCT04444752
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous(SC) injection
Trial: NCT00206622
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01952470
Drug: Isotonic Saline.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Trial: NCT04993222
Drug: AmBisome®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04169906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo once daily for 7 consective days
Trial: NCT04169906
Drug: TS-142, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days
Trial: NCT04169906
Drug: TS-142, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days
Trial: NCT04169906
Drug: TS-142, 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days
Trial: NCT03456609
Drug: shenqifuzheng injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
Trial: NCT00789828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
Trial: NCT02828228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once a day for 26 weeks
Trial: NCT01067859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of placebo during 48 hours
Trial: NCT02628769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02991508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04070755
Drug: FMX-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01611948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125mg/d placebo pill for 8 weeks
Trial: NCT02148783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03092089
Drug: Definity, (Lipid Microspheres) Intravenous Suspension
RxNorm normalized name: Definity, (lipid microspheres) intravenous suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
Trial: NCT00085735
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02615873
Drug: Accordion Pill™ Carbidopa/Levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
Trial: NCT02657486
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01824875
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02584244
Drug: LUM015
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00860574
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02014649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01192464
Drug: autologous CAR.CD30 EBV specific-CTLs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
Trial: NCT04322227
Drug: Placebo (treatment C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, BID capsules, orally
Trial: NCT02919306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
Trial: NCT00707850
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
Trial: NCT01187719
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
Trial: NCT02342249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo of Oseltamivir
Trial: NCT03343392
Drug: acetam/ketoro tromet group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
Trial: NCT03343392
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
Trial: NCT00161421
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food